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Abstract
Background: The TLR9 agonist CpG is increasingly applied in preclinical and clinical studies as a therapeutic modality to
enhance tumor immunity. The clinical application of CpG appears, however, less successful than would be predicted from
animal studies. One reason might be the different administration routes applied in most mouse studies and clinical trials.
We studied whether the efficacy of CpG as an adjuvant in cancer immunotherapy is dependent on the route of CpG
administration, in particular when the tumor is destructed in situ.
Methodology/Principal Findings: In situ tumor destruction techniques are minimally invasive therapeutic alternatives for
the treatment of (nonresectable) solid tumors. In contrast to surgical resection, tumor destruction leads to the induction of
weak but tumor-specific immunity that can be enhanced by coapplication of CpG. As in situ tumor destruction by
cryosurgery creates an instant local release of antigens, we applied this model to study the efficacy of CpG to enhance
antitumor immunity when administrated via different routes: peritumoral, intravenous, and subcutaneous but distant from
the tumor. We show that peritumoral administration is superior in the activation of dendritic cells, induction of tumor-
specific CTL, and long-lasting tumor protection. Although the intravenous and subcutaneous (at distant site) exposures are
commonly used in clinical trials, they only provided partial protection or even failed to enhance antitumor responses as
induced by cryosurgery alone.
Conclusions/Significance: CpG administration greatly enhances the efficacy of in situ tumor destruction techniques,
provided that CpG is administered in close proximity of the released antigens. Hence, this study helps to provide directions
to fully benefit from CpG as immune stimulant in a clinical setting.
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Introduction
Surgical resection of solid tumors generally offers the best
chance of cure in cancer patients. In many occasions however
tumor lesions are not eligible for resection and require alternative
destruction techniques, such as cryosurgery, radiofrequency or
laser ablation. These methods offer minimally invasive treatments
for a large range of tumors. In fact, radiofrequency was found to
provide local tumor control equivalent to resection in a subgroup
of patients [1], emphasizing that in situ tumor destruction
techniques become increasingly successful treatment modalities.
In contrast to surgical resection, in situ tumor destruction
provides an antigen source available for immune cells. The
involvement of the immune system in the clearance of tumor cells
is increasingly appreciated [2]. Antigen-presenting cells (APC),
such as dendritic cells (DC), are well-equipped to phagocytose
dying cells and process tumor antigens for presentation to T
lymphocytes [3]. Indeed, recent data demonstrated that DC in the
tumor draining lymph nodes efficiently acquire tumor debris
following in situ tumor destruction [4]. Unfortunately, although
tumor ablation has been associated with the occurrence of
immune activation in some patients [5], the outgrowth of distant
micrometastases implies that no or weak systemic protective
immune responses are induced.
Applying a recently developed mouse model we previously
showed that in situ tumor destruction by means of cryosurgery or
radiofrequency ablation led to the induction of weak but tumor-
specific immunity [6,7]. These results implied that the combina-
tion of in situ tumor destructive treatment modalities with specific
immune stimulation could be a strategy to enhance the clinical
outcome for an increasing number of cancer patients.
In this respect, toll-like receptor (TLR) agonists are of great
interest as immune adjuvants. TLR are a family of pathogen
recognition receptors that are triggered upon recognition of
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pathogen-associated molecular patterns expressed by a diverse
group of infectious microorganisms. Interestingly, the immunos-
timulatory potency of Bacille Calmette-Guerin (BCG), already
used in the 1970s to stimulate antitumor immunity [8], is now
known to be BCG DNA that binds to TLR9 [9,10]. Further
studies demonstrated that DC express TLR9 and are directly
activated through binding of TLR9 to unmethylated CpG motifs
in DNA [8]. DC activation by CpG involves a signaling cascade
culminating in the activation of transcription factors e.g. nuclear
factor-kB (NF-kB), subsequent upregulation of co-stimulatory
molecules and production of chemokines and cytokines (e.g. IL-6,
IL-12, TNF-a). As a result, CpG-stimulated DC induce Th1
responses and are instrumental for the activation of CD8+
cytotoxic T lymphocytes (CTL).
Indeed, we previously reported that antitumor responses were
synergistically enhanced when CpG was used as an adjuvant in the
cryo ablation model. Co-injection of CpG increased the formation
of tumor-specific CD8+ CTL and protected ,100% of the mice
against a re-challenge with tumor cells in this particular model [6].
In other models, CpG has been shown efficient in preventing
tumor outgrowth in a prophylactic setting and also eradicated
established tumors in mice [11,12]. The application of CpG in
clinical trials appears however less successful than would be
predicted from animal studies. A common argument used is the
differential expression of TLR9 in DC between mice and man.
TLR9 is abundantly expressed in plasmacytoid DC (pDC) from
mouse and man, and in murine myeloid DC (mDC). For human
mDC, TLR9 expression is less clear as some studies reported weak
to negative expression [13,14], while a recent study shows that
human mDC do contain TLR9 protein in amounts comparable
with pDC [15]. Moreover, mDC and pDC appear to be
functionally linked in both species as intensive cross-talk between
the DC subsets is essential for CpG-induced immune activation in
both mice and man [16,17].
We noted that in murine studies, showing the most potent CpG
effects, CpG is provided along with the antigen or in close
proximity to tumor antigens [12,18,19,20]. Moreover, we have
recently reported that co-localization of antigen and CpG within
the DC’s endosomal compartments in vivo is closely associated
with the capability to cross-present antigen and the induction of
subsequent protective immunity after ablation [21]. In clinical
studies the route of CpG administration is seldom based on the
location of the tumor but is generally directed by the supplier’s
regulations and/or the ease of administration. As these differences
in CpG administration routes may have major implications for its
clinical efficacy, we compared the efficacy of CpG administered
via different routes relative to the site of antigen availability in a
unique murine tumor ablation model. Our data show that the
intravenous (i.v.) and subcutaneous (s.c.) routes of CpG adminis-
tration (mostly applied in the human setting) are far less effective
than peritumoral (p.t.) CpG injections. We conclude that the
failure or success of CpG administration critically depends on
the location of CpG administration relative to the location of the
tumor.
Materials and Methods
Mice and Tumor Cells
C57BL/6n mice (6–8 weeks old) were purchased from Charles
River Wiga (Sulzfeld, Germany) and maintained under specific
pathogen-free barrier conditions at the Central Animal Labora-
tory (Nijmegen, The Netherlands). Drinking water and standard
laboratory food pellets were provided ad libitum and mice were
allowed to settle for at least 1 week before random assignment
into specific treatment groups. The experiments were performed
according to the guidelines for animal care of the Nijmegen
Animal Experiments Committee.
The OVA-transfected murine melanoma cell line B16F10
(B16OVA, clone MO5) was kindly provided by dr. K. Rock [22]
and cultured in complete medium (MEM, 5% fetal bovine serum
(Greiner Bio-one), 100 U/ml penicillin G sodium and 100 mg/ml
streptomycin (Pen/Strep), MEM sodium pyruvate (1 mM),
NaH2CO3, MEM vitamins, MEM non-essential amino acids (all
from Invitrogen), 20 mM b-mercaptoethanol (b-ME)) supplement-
ed with 30 mg/ml hygromycin and 1 mg/ml G418. The B16F10
melanoma cell line was obtained from the American Type Culture
Collection and maintained in complete medium.
Tumor Model and Cryosurgery
Tumor cells were suspended in a mixture of PBS and Matrigel
(2:1) and 0.5*106 cells in a total volume of 50 ml were injected s.c.
at the right femur. When tumor diameters measured between
6–8 mm (generally at day 9–10), mice were randomly assigned to
treatment groups (non-treated; NT, cryo ablation; cryo). Cryo
ablation was performed under isoflurane/O2/N2O anaesthesia
using a liquid nitrogen cryo ablation system (CS76, Frigitronics,
Shelton, CT) of which the tip is cooled by a continuous flow of
circulating liquid nitrogen. During 2 treatment cycles of freezing
and thawing the tumor was macroscopically frozen, while leaving
surrounding healthy tissue intact. To monitor the induction of
long-lasting tumor protection, mice were re-challenged with
25*103 B16OVA cells 40 days after cryo ablation. Two months
later, mice that survived the first tumor re-challenge received a
second re-challenge with 5*104 B16OVA or B16F10 cells. Mice
were sacrificed when tumor volume exceeded 1000 mm3 or when
tumors brake through the skin barrier.
CpG 1668 (95-TCCATGACGTTCCTGATGCT-39) with
phosphorothioated backbone was purchased from Sigma Genosys
(Haverhill, UK). CpG was injected in PBS p.t. (100 mg divided
over 3 injections of 10 ml surrounding the tumor), i.v. (100 mg in
100 ml), or s.c. (100 mg in 30 ml on the left femur of the mouse, i.e.
on the contra lateral side of the mouse referred to the location of
the tumor). Injections were performed within 30 minutes after
ablation. We used CpG 1668, which is a type B CpG, similar to
the clinical-grade available CpG currently used in clinical trials.
Enrichment and Analyses of DC
To analyze DC biology, DC were isolated from the inguinal
lymph nodes draining the tumor. Lymph nodes were excised and
mashed using needles or glass slides and digested in collagenase
type II and DNase for 15 min. After addition of EDTA and re-
suspending, cells were applied to a filter to remove debris and DC
were enriched by positive selection using anti-CD11c-labeled
(N418) magnetic micro beads (Miltenyi Biotec B.V.).
To study the fate of antigen and CpG after cryo ablation,
tumors were injected with fluorescently-labeled OVA protein
(OVA-Alexa488 or OVA-Alexa647, 20 mg/20 ml) and Cy5-
labeled CpG (CpG-Cy). CD11c-enriched cells were incubated
with Fc Block (CD16/CD32; 2.4G2) and stained with anti-CD11c
(HL3), biotinylated anti-CD80 (1G10/B7) or isotype controls and
streptavidin-PE, all obtained from BD Biosciences. Expression of
CD80 was analyzed in OVA+ and OVA2 cells gated on CD11c+
cells by flow cytometry (FACS Calibur, Becton Dickinson & Co,
San Jose, CA). It was previously reported that uptake of the model
antigen OVA by bone marrow-derived DC largely depends on the
mannose receptor [23]. Therefore, we repeated our experiments
with BSA-Alexa488 and no differences in uptake by DC in vivo
were observed between the two antigens (data not shown).
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PLoS ONE | www.plosone.org 2 December 2009 | Volume 4 | Issue 12 | e8368
Ex Vivo T Cell Monitoring
Cells from the spleen and tumor draining lymph nodes were
stimulated for 5 hours with PMA (0.5 mg/ml)/ionomycin (0.1 mg/
ml) in the presence of Brefeldin A (10 mg/ml). Cells were analyzed
for CD8 and intracellular expression of IFN-c using flow
cytometry. In addition, cells were stimulated with anti-CD3 or
OVA protein for 96 hours to analyze the secretion of IFN-c in
supernatant. The IFN-c ELISA was performed according to the
manufacturer’s instructions (BD Biosciences).
Antigen-Specific CTL
To study the efficacy of the differential CpG administration to
induce antigen-specific CTL, spleens and tumor-draining lymph
nodes were isolated ten days after ablation. Mixed cell suspensions
of lymph node and spleen were plated in 24-well plates in
complete IMDM supplemented with hIL2 (10 U/ml) and
stimulated with irradiated (1600 rad) B16OVA cells (5*104 cells/
well) that had been treated overnight with r-IFN-c (50 U/ml) to
up-regulate MHC class I presentation. At day 3–4 of culture, cells
were harvested and dead cell debris was removed using a Ficoll
gradient. Cells were cultured in fresh 24-well plates for another
4–5 days. To visualize tumor-specific CTL, cells were stained
with FITC-conjugated CD4 (L3T4) or CD8 (53–6.7) and APC-
conjugated OVA Kb tetramers (Sanquin, Amsterdam, The
Netherlands) and analyzed by flow cytometry.
Statistical Analyses
Data were analyzed using a two-tailed Student’s T test or one-
way ANOVA for multiple comparisons with Bonferroni as post
hoc test.
Results
Accumulation of Activated Antigen-Loaded Mature
Dendritic Cells in Draining Lymph Nodes Depends on the
Route of CpG
The priming of CD8+ CTL depends on the unique feature of
DC to capture extracellular antigens and present them on MHC
class I. This process, known as cross-presentation [24], can be
strongly enhanced by activation of DC via TLR9 [25]. In the
present study, we investigated the impact of the route of CpG
administration on DC function and antitumor responses after cryo
ablation.
As shown in Figure 1A, peritumoral CpG injections markedly
increased the absolute number of DC that accumulated in the
tumor-draining lymph node 2 days after injection in both tumor-
bearing non-treated mice and in mice subjected to cryosurgery.
Subcutaneous injection of CpG at the contra lateral side did not
affect the numbers of DC. Interestingly, i.v. CpG injections
increased the accumulation of CD11c+ DC in the tumor-draining
lymph node only when combined with cryo ablation (Fig. 1A).
Antigen internalization and the maturation status of DC are two
major requirements for the induction of productive antigen-
specific immune responses. We have previously shown that cryo
ablation combined with p.t. CpG administration synergistically
up-regulates the expression of co-stimulatory molecules [26]. To
study whether the route of CpG administration differentially
affects the ability of DC to take up antigen, OVA-Alexa-488 was
injected in the tumor just prior to ablation as a surrogate marker
for soluble antigens that are rapidly released from the tumor
following cryosurgery [27]. Peritumoral CpG injection concurrent
with ablation synergistically increased the uptake of antigen by
draining lymph node DC. In contrast, both i.v. and s.c. injections
failed to enhance antigen uptake in either tumor-bearing non-
treated mice or mice subjected to cryosurgery (Fig. 1B–C).
Applying fluorescently-labeled CpG, we additionally found that
the majority of all lymph node DC from mice exposed to CpG via
p.t. or i.v. injections had internalized CpG. The amount of CpG
per DC was however much higher after p.t. administration
(Fig. 1D) and the OVA+ DC had acquired increased levels of CpG
compared to the OVA+ DC from mice that received i.v. CpG
injections. Finally, s.c. and i.v. CpG injections only slightly
increased CD80 expression on antigen-loaded DC, whereas
p.t. CpG administration significantly enhanced the levels of
co-stimulatory markers (Fig. 1E).
Together, these results demonstrate that p.t. CpG injections
significantly increase the numbers of antigen- and CpG-loaded,
CD80-expressing draining lymph node DC after cryo ablation in
vivo. Administering CpG via the i.v. route results in the
accumulation of draining lymph node DC after ablation but these
DC exhibit only slightly enhanced levels of internalized antigen
and CD80-expression when compared to cryo ablation alone.
Subcutaneous injections of CpG at the contra lateral side do
increase the number of DC in the local lymph node (data not
shown), but not in the tumor-draining lymph node and fail to
enhance antigen uptake and CD80 expression.
Route of CpG Administration Determines Priming of
CD4+ and CD8+ T Cells
To gain further insight into the consequences of differential DC
phenotypes induced by CpG administration via different routes in
vivo the splenocytes and lymphocytes from the tumor draining
lymph nodes were analyzed. We observed that the percentages of
IFN-c+ CD4+ and IFN-c+ CD8+ T cells after non-specific (Fig. 2A)
or specific re-stimulation (Fig. 2B), as well as the cellularity of the
lymphoid organs (not shown) were affected by the CpG injection
site. Peritumoral CpG injections increased IFN-c+ cells predom-
inantly in the tumor-draining lymph node and also slightly in the
spleen. After i.v. injections the number of IFN-c+ cells was mainly
increased in the spleen. CD8+ IFN-c+ T cells were slightly
enhanced in the lymph node draining the ablated site. Subcuta-
neous CpG injections contra lateral of the tumor did not affect
IFN-c+ T cell numbers in the tumor-draining lymph node.
Finally, enumeration of OVA-specific CD8+ T cells 10 days
after cryosurgery confirmed the superior induction of antigen-
specific CTL when CpG was administered p.t. (3.1%61.1 of all
CD8+, Fig. 3). Relative to cryo ablation alone (0.7%60.2), neither
i.v. nor s.c. CpG injections yielded a significant increase in CTL
(1.5%60.4; 0.60%60.2). The same trend, although not signifi-
cant, was found for CTL specific for B16 intrinsic tumor peptide
TRP-2 (not shown).
Collectively, these data thus indicate that the improved loading
and maturation of DC following p.t. CpG administration
correlates with the observed increase in local lymphocyte
activation.
Peritumoral CpG Injections Are Superior in the Induction
of Long-Term Antitumor Immunity
The aforementioned data show that the injection site of CpG
relative to the ablated tumor area is a crucial determinant in the
induction of tumor-specific CTL responses. To further investigate
its importance, tumor-bearing mice were treated with cryo
ablation and CpG was given either p.t., s.c. or i.v. Forty days
after ablation, tumor-free mice were challenged with a lethal dose
of tumor cells.
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Figure 1. Quantity and quality of lymph node DC. (A) Absolute numbers of CD11c+ cells in the draining lymph nodes 2 days after ablation.
Tumor-bearing mice were left untreated (NT) or were subjected to cryo ablation (cryo). In addition, some groups of mice received CpG via the
indicated routes. Brackets indicate significant differences (p,0.05) between indicated groups (n = 4–6/group, 2 similar experiments). (B) Uptake of
antigen after cryo ablation. OVA-Alexa488 was injected in B16OVA tumors (6–9 mm) just prior to cryo ablation to monitor the fate of antigen after in
situ tumor destruction. Mice were additionally treated with CpG via the indicated routes. Two days after ablation, the uptake of antigen was analyzed
in CD11c+ cells enriched from pools of tumor-draining lymph nodes. Numbers in the panels indicate the percentage of OVA+ of all CD11c+ cells. Data
from one representative mouse is shown per group. (C) Quantitative analyses of replicates of experiments as shown in (B) (5 mice/group,
representative of 2 experiments). (D) Uptake of antigen and CpG by CD11c+ cells monitored after p.t. and i.v. CpG-Cy5 administration and intra-
tumoral injection of OVA-Alexa488. Data from one representative mouse is shown (n = 4/group). (E) The expression of CD80 on CD11c+ antigen-
loaded cells. * indicates significantly different (p,0.05) from all other groups (n = 5/group, 2 similar experiments).
doi:10.1371/journal.pone.0008368.g001
Route of CpG Administration
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Cryosurgery combined with p.t. CpG administrations protected
,90% of all mice, whereas s.c. and i.v. CpG injections failed to
significantly improve the responses induced by cryosurgery alone
(Fig. 4A). Although i.v. CpG administration failed to increase
survival, the tumor growth was considerably slower than in mice
treated with s.c. injections or with cryo ablation alone (Fig. 4B).
These data indicate that i.v. CpG injections may induce antitumor
responses that are able to limit tumor growth and prolong survival
to some extent. Nevertheless, when mice received lethal tumor
challenges i.v. CpG injections protected only 50% of the mice,
Figure 2. Route of CpG administration affects T cell activation. (A) Percentages of IFN-c+ T cells within the CD4+ or CD8+ populations after
cryo ablation +/2 CpG. B16-OVA tumor-bearing mice were treated with cryo ablation combined with CpG administration via the indicated routes.
Seven days after ablation, spleen, tumor-draining lymph nodes and non-draining lymph nodes were isolated. Cells were stimulated with PMA/
ionomycin and stained for CD8, CD4 and IFN-c. * indicate significant differences (p,0.05) between the indicated CpG-treated group and the Naı¨ve
and Cryo group. (B) IFN-c production after cryo ablation +/2 CpG. Cells were stimulated with OVA for 96 hours and IFN-c was measured in
supernatant by ELISA. The mean levels of the Cryo+CpG i.v. groups in both organs are significantly different from all other groups (n = 6/group, 2
experiments).
doi:10.1371/journal.pone.0008368.g002
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whereas in case of p.t. CpG injections ,90% of the mice survived.
CpG pre-treatment of naive mice did not provide any protection
against lethal tumor challenges irrespective of the administration
route (data not shown).
We have previously shown that the timing of CpG administration
is critical for the efficacy of p.t. CpG injections when combined with
ablation. The reduced efficacy of i.v. administered CpG in the
current experiments may therefore relate to the delay in which
CpG-ODN reach the released antigens at the ablation site. CpG
was therefore injected 1 day before, concurrent with, or 1 day after
ablation. Administration of CpG 1 day before ablation resulted in
similar results as observed for CpG injections concurrent with
ablation (40–45% of the mice survived). In contrast, CpG
administration 1 day after ablation failed to enhance antitumor
immunity as induced by cryo ablation alone (Fig. 5). The reduced
efficacy of i.v. CpG administrations compared to p.t. exposure is
thus not due to timing aspects.
Discussion
Although mouse models have clearly shown the potent
antitumor effects of CpG, clinical results have so far been
disappointing, with recent phase 2 and 3 trials in non-small cell
lung cancer being dropped due to the failure of s.c. CpG-ODN
administration to improve clinical outcome [28]. In the present
study, we show that the route of administration determines the
efficacy of CpG to stimulate immune responses after in situ tumor
destruction. Peritumoral CpG administration increases the
numbers of activated, mature, antigen-bearing DC in the tumor-
draining lymph node and stimulates the formation of tumor-
specific CTL leading to superior memory responses against tumor
antigens. Subcutaneous CpG injections distant from the tumor fail
to enhance antitumor immunity. Also systemic CpG administra-
tion through i.v. injection only provides limited protection (50%)
as compared to peritumoral injection (90% protection).
Applying a novel clinically relevant in situ tumor destruction
model, we have previously reported that the failure or success of
CpG as a vaccine adjuvant depends on the co-localization of
antigen and CpG within endosomal DC compartments and hence
on the timing of CpG administration. Dendritic cells were only
able to cross-present antigens and promote CTL induction in
conditions where antigen and CpG were co-localized within DC.
In fact, p.t. CpG administration 1 day before or after tumor
ablation, instead of concomitant CpG injection, already had a
major impact on its efficacy [21]. Based on these findings, we set
out to determine the effect of the route of administration on CpG
in this model system. While s.c. CpG injections distant from the
tumor fail to initiate any antitumor immunity, i.v. CpG
administration yielded some survival benefit (not significant) over
cryo ablation alone. These differences in the efficacy of CpG did
not relate to differences in timing, as different timing regimens
for i.v. CpG administration did not improve its efficacy. These
Figure 3. Route of CpG administration determines induction of tumor-specific CTL. (A) Representative dot plots of CD8+OVA-Kb tetramer+
cells of individual mice. Mice bearing B16OVA tumors (6–9 mm) were subjected to cryo ablation alone or received additional CpG injections via the
indicated routes. Ten days after tumor destruction, cells from spleen and tumor draining lymph nodes were isolated and re-stimulated with IFN-c-
treated c-irradiated B16OVA tumor cells. Cultures were cleaned by a Ficoll step after 3–4 days of culture and at day 8–9 cells were analyzed for the
presence of tumor-specific CTL using APC-labeled OVA-Kb tetramers. Cells were gated on CD8
+ T cells. Data from one representative mouse per
group is shown. (B) Quantitative analyses of collective data as shown in (A) (mean levels of 2 separate experiments (4–6 mice per group/experiment)).
* indicates significant differences (p,0.05) of the indicated group compared to all other groups.
doi:10.1371/journal.pone.0008368.g003
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data show that both the time and route of CpG administration
determine the efficacy of CpG therapy and imply that the
availability of CpG in time and place in (lymphoid) tissues is an
important factor in the adjuvanticity of CpG.
It has previously been postulated that the outcome of CpG-
ODN administration via a specific route may depend on the type
of cells that are encountered by the ODN at a particular
anatomical site [29]. The responsive cells in the lymph nodes
draining the injection site may activate a different pathway for
TLR9 signaling than cells in the spleen. In agreement with this
hypothesis are the observations that intra-tumoral [25], p.t.
[26,30] or intra-lymphatic [31] administration of CpG showed
the anticipated Th1-promoting effect and were highly efficient in
improving T cell-mediated immunity. In contrast, systemic (i.v. or
i.p.) application of CpG resulted in T cell suppression rather than
immune activation [32,33,34]. Similar indications came from
human trials in which s.c. administrations of antigen plus CpG
induced a systemic Th1-like cytokine expression in serum, whereas
intravenous injections caused no such effects [35].
Here we show that DC taken from the tumor-draining lymph
node after i.v. CpG exposure have internalized suboptimal levels
of antigen and fail to express high levels of co-stimulatory
molecules. This may be due to the inability of incoming DC to
internalize or transfer antigen after a previous encounter with
CpG. As both resident DC and migrating DC are required for the
induction of productive CTL priming [36] this may limit the
induction of functional CTL. In addition, it was previously
shown that i.v. administration induced expression of indoleamine
Figure 4. Route of CpG administration determines efficacy of antitumor immunity. (A) Kaplan-Meier survival curves of naı¨ve mice versus
mice that have been treated with cryo ablation alone, or in combination with concurrent CpG administration via the indicated routes. Established
B16OVA tumors on the right femur were treated with cryo ablation alone or in combination with CpG administrations via different routes: p.t., i.v., or
s.c. contra lateral of the tumor. Forty days later, naı¨ve and tumor-free mice (8–13 mice per group) received a s.c. re-challenge with tumor cells (25.000
B16OVA cells). (B) Tumor size determined every 2–3 days after treatment. Data is representative of two independent experiments.
doi:10.1371/journal.pone.0008368.g004
Figure 5. Timing of i.v. CpG injections determines antitumor
immunity. Established B16OVA tumors were treated with cryo ablation
alone or in combination with i.v. CpG administration concurrent with
ablation, or 1 day before or after ablation. Forty days later, naı¨ve and
treated tumor-free mice (7–10 mice per group) received a s.c. re-challenge
with tumor cells (25.000–50.000 B16OVA cells) on the contra-lateral flank
and survival was monitored. Representative of 2 experiments is shown.
doi:10.1371/journal.pone.0008368.g005
Route of CpG Administration
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2,3-dioxygenase (IDO) in DC, an enzyme linked to immune
regulation and formation of regulatory T cells (Treg), leading to
suppressed T cell expansion and CTL activity. Although we did
not investigate the immune regulatory properties of DC directly,
we observed significantly increased numbers of CD4+Foxp3+ Treg
in the spleen of mice treated i.v. with CpG (data not shown). Treg
hamper the induction of antitumor immune responses and are
known to be regulated via multiple mechanisms [37]. The
observed sub-optimal maturation of DC in the tumor draining
lymph node combined with the induction of IDO-expressing DC
in the spleen following i.v. CpG administration may prevent
optimal immune activation.
The present study emphasizes that in cancer immunotherapy
CpG should be administered in close proximity of the released
tumor antigens. In clinical studies CpG is generally administered
independent of tumor antigen release [38]. From a clinical point of
view it is preferred to administer CpG at an easy accessible
location and in large amounts according to the rationale that it will
travel to the tumor location. However, we show here that neither
s.c. administration on a distant site or i.v. injection fully exploit the
adjuvant capacity of CpG. In line with our data showing that co-
localization of antigen and CpG favours immunity, potent
immune stimulatory responses of CpG were found also in humans
when antigen (recombinant hepatitis B surface antigen) and CpG
(CPG 7909) were co-injected [39].
It would be interesting to see if the findings presented here also
apply to other situations of tumor cell death, like that in
chemotherapy or radiation. Nevertheless, as both cryosurgery,
and other in situ tumor destruction treatments (e.g. radiofrequency
ablation or high-intensity focussed ultrasound) are applied in
patients, the combinational therapy with CpG as described in this
paper is clinically relevant. The instantaneous availability of tumor
antigens and destruction of the majority of tumor tissue with
ablation treatments may provide a scenario in which the effects of
CpG can be appreciated even in advanced disease. Our data
emphasize that the location of CpG administration should be an
imperative element in the design of future clinical trials.
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